PraneethChebroluMDMSCR

Research • Peoria, IL

Director Clinical Research

Join to view full profile

Dr. Chebrolu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chebrolu's full profile

Already have an account?

Office
530 NE Glen Oak Ave
1106
Peoria, IL 61637
Phone+1 309-624-5419

Fax+1 312-942-0729

Summary

Dr. Praneeth Chebrolu is the Director of Clinical Research in Peoria, IL. Dr. Chebrolu received medical degree from NTR University of Health Sciences, India with a masters in Clinical Research from Rush University in Chicago and has extensive Drug Development experience in areas of Oncology, Neurology, COVID-19, and PASC

Education & Training

Rush University Medical Center MS, Clinical Research , 2015 - 2018
OtherClass of 2011, MBBS

Clinical Trials

Dendritic Cell Cancer Vaccine for High-grade Glioma Start of enrollment: 2010 Apr 01
Completed
Phase 2
A Phase 3 Study of Tanezumab for Chronic Low Back Pain Start of enrollment: 2015 Aug 18
Completed
Phase 3
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation Start of enrollment: 2015 Dec 30
Completed
Phase 3
Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee Start of enrollment: 2016 Jan 21
Completed
Phase 3
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy Start of enrollment: 2017 Dec 08
Completed
Phase 3
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation Start of enrollment: 2023 Aug 14
Recruiting
Phase 2
Tumor Electric Fields Treatment System for Glioblastoma Start of enrollment: 2020 Apr 07
Recruiting
Early Phase 1
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer Start of enrollment: 2020 Jul 09
Completed
Phase 1
Join now to see all

Publications & Presentations

Other

Survival Analysis of Newly Diagnosed Glioblastoma Patients on Adjuvant Treatment with Temozolomide ≥ Six Cycles
Praneeth Chebrolu, ProQuest
https://search-proquest-com.ezproxy.rush.edu/docview/2039182028/6123CCB292894632PQ/8?accountid=28534
4/2018

Grant Support

Rush Translation Science Consortium - COVID19Rush University2020–Present